Equities research analysts expect Chimerix Inc. (NASDAQ:CMRX) to report earnings per share of ($0.43) for the current quarter, Zacks reports. Four analysts have made estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.45). Chimerix posted earnings of ($0.38) per share during the same quarter last year, which indicates a negative year over year growth rate of 13.2%. The business is expected to report its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.79) per share for the current year, with EPS estimates ranging from ($1.87) to ($1.64). For the next financial year, analysts forecast that the firm will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.97) to ($1.20). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.07. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. The firm had revenue of $1.84 million during the quarter, compared to analysts’ expectations of $0.83 million.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. increased its holdings in Chimerix by 112.3% in the third quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock valued at $1,055,000 after buying an additional 106,267 shares in the last quarter. Nationwide Fund Advisors increased its holdings in Chimerix by 70.3% in the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 24,994 shares in the last quarter. Prosight Management LP purchased a new position in Chimerix in the fourth quarter valued at $6,846,000. Ascend Capital LLC increased its holdings in Chimerix by 96.9% in the fourth quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock valued at $3,240,000 after buying an additional 344,311 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Chimerix in the fourth quarter valued at $280,000. 74.39% of the stock is owned by institutional investors.
Shares of Chimerix stock opened at $5.06 on Wednesday. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.24.
TRADEMARK VIOLATION WARNING: This piece was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://dakotafinancialnews.com/2018/04/14/chimerix-inc-cmrx-expected-to-announce-earnings-of-0-43-per-share.html.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.